Skip to main content

Innoviva (INVA) Gets a Buy from Cantor Fitzgerald

Tipranks - Tipranks - Fri Feb 27, 7:49AM CST

In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Innoviva, with a price target of $32.00. The company’s shares closed yesterday at $24.24.

Claim 50% Off TipRanks Premium

Seedhouse covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Innoviva, and Korro Bio. According to TipRanks, Seedhouse has an average return of 10.5% and a 43.49% success rate on recommended stocks.

Currently, the analyst consensus on Innoviva is a Strong Buy with an average price target of $37.00, implying a 52.64% upside from current levels. In a report released today, TipRanks – xAI also reiterated a Buy rating on the stock with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Innoviva’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $107.8 million and a net profit of $89.91 million. In comparison, last year the company earned a revenue of $89.51 million and had a net profit of $1.21 million

Read More on INVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).